Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapy with glatiramer acetate for multiple sclerosis.

L Munari1, R Lovati, A Boiko

  • 1Azienda Ospedaliera Ospedale Niguarda Ca' Granda, P.zza Ospedale Maggiore, 3, Milan, Italy.

The Cochrane Database of Systematic Reviews
|February 20, 2004
PubMed
Summary

Glatiramer acetate (Copaxone) did not demonstrate significant benefits for multiple sclerosis (MS) progression or relapses in a Cochrane review. Routine clinical use is not currently supported due to a lack of efficacy and potential side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Taking care of people experiencing homelessness: a community case study on the practice of the Volunteer Association "A doctor for you" in Brescia, Italy.

Frontiers in public health·2025
Same author

Fluorescence relaxation kinetics of poly(methylphenylsilane) film and nanocomposites.

Nanoscale research letters·2016
Same author

Selective brain region activation by histamine H₃ receptor antagonist/inverse agonist ABT-239 enhances acetylcholine and histamine release and increases c-Fos expression.

Neuropharmacology·2013
Same author

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

Lancet (London, England)·2008
Same author

Generation of 5-fs pulses and octave-spanning spectra directly from a Ti:sapphire laser.

Optics letters·2007
Same author

Vitamin E intake and quality of life in amyotrophic lateral sclerosis patients: a follow-up case series study.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2006

Area of Science:

  • Neuroscience
  • Immunology
  • Clinical Trials

Background:

  • Glatiramer acetate (Copaxone), a synthetic amino acid polymer, has been investigated for its potential to improve outcomes in multiple sclerosis (MS).
  • Previous findings suggested a possible suppressive effect on experimental allergic encephalomyelitis (EAE), an animal model of MS.

Purpose of the Study:

  • To conduct a comprehensive Cochrane review of all randomized, placebo-controlled trials evaluating glatiramer acetate in patients with multiple sclerosis (MS).
  • To assess the efficacy of glatiramer acetate across different courses of MS, including relapsing-remitting (RR) and chronic progressive (CP) forms.

Main Methods:

  • Systematic search of multiple databases (Cochrane MS Group, CENTRAL, MEDLINE, EMBASE) and hand searching of symposia reports up to June 2003.

Related Experiment Videos

  • Inclusion of all randomized controlled trials (RCTs) comparing glatiramer acetate with placebo in definite MS patients, irrespective of administration schedule or disease course.
  • Analysis of data from 646 patients, with attention to methodological quality and potential impact of side effects on blinding.

    • Main Results:

    • Glatiramer acetate showed no significant effect on disease progression as measured by the Expanded Disability Status Scale (EDSS).
    • A slight decrease in mean EDSS score was observed in one major study but had limited validity.
    • No significant benefit was found in CP MS patients. The most common systemic adverse event was transient flushing, while local injection-site reactions occurred in up to half of patients.

    Conclusions:

    • Glatiramer acetate did not demonstrate beneficial effects on primary outcome measures for MS, including disease progression and clinical relapse risk.
    • The current evidence does not support the routine use of glatiramer acetate in clinical practice for MS management.
    • Further research is recommended to develop more reliable disability measures and incorporate quality of life as a primary outcome in MS studies.